Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H11NO3 |
Molecular Weight | 169.1778 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC=C(CO)C(CO)=C1O
InChI
InChIKey=LXNHXLLTXMVWPM-UHFFFAOYSA-N
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00165Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html
Sources: http://www.drugbank.ca/drugs/DB00165
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.
CNS Activity
Originator
Sources: http://www.bendectin.com/en/
Curator's Comment: The combination of doxylamine and vitamin B6 (PYRIDOXINE) was first introduced to the US market as Bendectin in 1956 by the Wm. S. Merrell Company of Cincinnati, Ohio.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21944860 |
8.3 mM [Ki] | ||
Target ID: CHEMBL5960 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21462331 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | PYRIDOXINE HYDROCHLORIDE Approved UsePyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following:
Inadequate dietary intake.
Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.
Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
189.6 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
58.9 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
62 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
33.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
2183.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
48.2 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
12.7 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
38.9 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
47.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
372.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
85.9 ng/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
30.1 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
27.4 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30.2 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
892.9 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1750.3 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
4-PYRIDOXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1511.3 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
233.6 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
244 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
249.2 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
18603.4 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
80 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
27 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
35.1 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
42.5 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2008.9 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1742.3 ng × h/mL |
20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1076.2 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1021.7 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1064.6 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
19420.2 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PYRIDOXAL PHOSPHATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18543.1 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
4-PYRIDOXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12.5 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXAL blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
1.2 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT |
|
0.4 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.4 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: doxylamine succinate(10 mg; 2 per day (up to 4)) Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
pregnant, mean age 26 years n = 133 Health Status: pregnant Age Group: mean age 26 years Sex: F Population Size: 133 Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
Disc. AE: Somnolence, Syncope... AEs leading to discontinuation/dose reduction: Somnolence (1.5%) Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82Syncope (0.7%) Dizziness (0.7%) |
117 mg multiple, oral (mean) Studied dose |
unhealthy, mean age 41.5 years n = 172 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 41.5 years Sex: F Population Size: 172 Sources: |
Disc. AE: Paraesthesia, Muscle weakness... AEs leading to discontinuation/dose reduction: Paraesthesia (34%) Sources: Muscle weakness (19.2%) Numbness (12.2%) |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Disc. AE: Depression, Headache... AEs leading to discontinuation/dose reduction: Depression (79%) Sources: Headache (48%) Tiredness (59%) Irritability (38%) Neuropathy (40%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 0.7% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: doxylamine succinate(10 mg; 2 per day (up to 4)) Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
pregnant, mean age 26 years n = 133 Health Status: pregnant Age Group: mean age 26 years Sex: F Population Size: 133 Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
Syncope | 0.7% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: doxylamine succinate(10 mg; 2 per day (up to 4)) Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
pregnant, mean age 26 years n = 133 Health Status: pregnant Age Group: mean age 26 years Sex: F Population Size: 133 Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
Somnolence | 1.5% Disc. AE |
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: doxylamine succinate(10 mg; 2 per day (up to 4)) Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
pregnant, mean age 26 years n = 133 Health Status: pregnant Age Group: mean age 26 years Sex: F Population Size: 133 Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82 |
Numbness | 12.2% Disc. AE |
117 mg multiple, oral (mean) Studied dose |
unhealthy, mean age 41.5 years n = 172 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 41.5 years Sex: F Population Size: 172 Sources: |
Muscle weakness | 19.2% Disc. AE |
117 mg multiple, oral (mean) Studied dose |
unhealthy, mean age 41.5 years n = 172 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 41.5 years Sex: F Population Size: 172 Sources: |
Paraesthesia | 34% Disc. AE |
117 mg multiple, oral (mean) Studied dose |
unhealthy, mean age 41.5 years n = 172 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 41.5 years Sex: F Population Size: 172 Sources: |
Irritability | 38% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Neuropathy | 40% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Headache | 48% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Tiredness | 59% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Depression | 79% Disc. AE |
175 mg multiple, oral Studied dose |
unhealthy, mean age 42 years n = 58 Health Status: unhealthy Condition: premenstrual syndrome Age Group: mean age 42 years Sex: F Population Size: 58 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19637937/ Page: 12.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Neonatal pyridoxine responsive convulsions due to isoniazid therapy. | 1976 Jul |
|
Molecular genetic analysis of pyridoxine-nonresponsive homocystinuric siblings with different blood methionine levels during the neonatal period. | 1999 Aug |
|
Acute isoniazid neurotoxicity during preventive therapy. | 2000 Feb |
|
Clinical and institutional aspects of antidote therapy in Russia. | 2001 |
|
Drug treatment for tuberculosis during pregnancy: safety considerations. | 2001 |
|
[Evaluation of vitamin B6 and calcium pantothenate effectiveness on hair growth from clinical and trichographic aspects for treatment of diffuse alopecia in women]. | 2001 |
|
Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. | 2001 |
|
Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data. | 2001 |
|
Dietary intake as a cardiovascular risk factor in Costa Rican adolescents. | 2001 Apr |
|
Effect of energy restriction and exercise on vitamin B-6 status of women during lactation. | 2001 Apr |
|
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. | 2001 Apr |
|
Association of the B-vitamins pyridoxal 5'-phosphate (B(6)), B(12), and folate with lung cancer risk in older men. | 2001 Apr 1 |
|
Experimental model of pyridoxine (B6) deficiency-induced neuropathy. | 2001 Aug |
|
Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol. | 2001 Aug |
|
Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? | 2001 Feb |
|
A modified dialyzer with vitamin E and antioxidant defense parameters. | 2001 Feb |
|
Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. | 2001 Feb 1 |
|
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. | 2001 Feb 20 |
|
Analyzing counts, durations, and recurrences in clinical trials. | 2001 Feb-May |
|
Pyridoxine dependent and pyridoxine responsive seizures. | 2001 Jan |
|
Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients. | 2001 Jan |
|
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways. | 2001 Jan |
|
Determination of vitamin B(6) in cooked sausages. | 2001 Jan |
|
Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. | 2001 Jan |
|
Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. | 2001 Jan |
|
Hyperhomocysteinemia in renal transplant patients: an independent factor of cardiovascular disease. | 2001 Jan-Feb |
|
Long-term effects of vitamin B(12), folate, and vitamin B(6) supplements in elderly people with normal serum vitamin B(12) concentrations. | 2001 Jan-Feb |
|
Hyperhomocysteinemia is associated with venous thrombosis in patients with short bowel syndrome. | 2001 Jan-Feb |
|
Thiamine, riboflavin, pyridoxine, and vitamin C status in premature infants receiving parenteral and enteral nutrition. | 2001 Jul |
|
Multi-task flow system for potentiometric analysis: its application to the determination of vitamin B6 in pharmaceuticals. | 2001 Jul |
|
Pyridoxine-dependent and pyridoxine-responsive seizures. | 2001 Jun |
|
Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with diet. | 2001 Jun |
|
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor. | 2001 Jun |
|
Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria. | 2001 Jun |
|
Light-dependent generation of reactive oxygen species in cell culture media. | 2001 Jun 15 |
|
Risk and uncertainty. | 2001 Jun 21 |
|
Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. | 2001 Mar |
|
CSF glutamate/GABA concentrations in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control. | 2001 Mar |
|
Occupational and systemic contact dermatitis with photosensitivity due to vitamin B6. | 2001 Mar |
|
High cysteine levels in renal transplant recipients: relationship with hyperhomocysteinemia and 5,10-MTHFR polymorphism. | 2001 Mar 27 |
|
Homocysteine--an innocent bystander in vascular disease? | 2001 May |
|
Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. | 2001 May 29 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/pyridoxine.html
Usual Adult Dose for Dietary Supplement
Pyridoxine Deficiency:
10 to 25 mg/day orally, IM, or IV for 3 weeks followed by 2 to 5 mg/day from a multivitamin product.
Usual Adult Dose for Anemia
Sideroblastic, hereditary: 200 to 600 mg orally daily. If adequate response obtained, dose may be decreased to 30 to 50 mg orally daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11605018
Pyridoxine (5 mmol/l) caused complete inhibition of microvessel outgrowth in rat aortic rings
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
26915-9
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
LOINC |
2900-9
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
NDF-RT |
N0000192800
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1673
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
LIVERTOX |
1035
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
DSLD |
3308 (Number of products:6)
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
DSLD |
3377 (Number of products:257)
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
WHO-ATC |
J04AM08
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
334311
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
LOINC |
75043-0
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
NCI_THESAURUS |
C1334
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
WHO-VATC |
QA11HA02
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
CFR |
21 CFR 102.23
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
LOINC |
39786-9
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
WHO-ATC |
A11HA02
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
DSLD |
2695 (Number of products:1886)
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
||
|
DSLD |
110 (Number of products:1286)
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080848
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
KV2JZ1BI6Z
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
2216
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
200-603-0
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
16709
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
759148
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
684879
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL1364
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
DTXSID4023541
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
1054
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
m9365
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
C62619
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
PYRIDOXINE
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
SUB10168MIG
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
42954
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
ALTERNATIVE | |||
|
D011736
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
KV2JZ1BI6Z
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
27306
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
2836
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
65-23-6
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
SUB126944
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY | |||
|
DB00165
Created by
admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)